about
Prevention of respiratory syncytial virus infection in infantsLack of evidence for the efficacy of enhanced surveillance compared to other specific interventions to control neonatal healthcare-associated infection outbreaksReported rates of diarrhea following oral penicillin therapy in pediatric clinical trialsAntibiotic preferences for childhood pneumonia vary by physician type and European regionA time for action: antimicrobial resistance needs global response.Changing indications and socio-demographic determinants of (adeno)tonsillectomy among children in England--are they linked? A retrospective analysis of hospital data.Quantifying the Burden of Hospital-Acquired Bloodstream Infection in Children in England by Estimating Excess Length of Hospital Stay and Mortality Using a Multistate Analysis of Linked, Routinely Collected Data.Selecting appropriate empirical antibiotic regimens for paediatric bloodstream infections: application of a Bayesian decision model to local and pooled antimicrobial resistance surveillance data.Antibiotic Prescriptions and Prophylaxis in Italian Children. Is It Time to Change? Data from the ARPEC Project.Increasing short-stay unplanned hospital admissions among children in England; time trends analysis '97-'06Surveillance of Gram-negative bacteria: impact of variation in current European laboratory reporting practice on apparent multidrug resistance prevalence in paediatric bloodstream isolatesAntibiotic prescribing in general practice and hospital admissions for peritonsillar abscess, mastoiditis, and rheumatic fever in children: time trend analysisCurrent evidence for the use of paediatric antiretroviral therapy--a PENTA analysis. Paediatric European Network for the Treatment of AIDS Steering Committee.Antibiotic dosing in children in Europe: can we grade the evidence from pharmacokinetic/pharmacodynamic studies - and when is enough data enough?Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study.Basic epidemiology and immunopathology of RSV in children.Tonsillectomy among children with low baseline acute throat infection consultation rates in UK general practices: a cohort study.Systemic antifungal prescribing in neonates and children: outcomes from the Antibiotic Resistance and Prescribing in European Children (ARPEC) StudyRisk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study.Improving antibiotic prescribing for children in the resource-poor setting.Syphilis in London circa 2004: new challenges from an old disease.Valganciclovir for symptomatic congenital cytomegalovirus diseaseAntibiotic Resistance Prevalence in Routine Bloodstream Isolates from Children's Hospitals Varies Substantially from Adult Surveillance Data in Europe.Impact of UK Primary Care Policy Reforms on Short-Stay Unplanned Hospital Admissions for Children With Primary Care-Sensitive Conditions.Increasing skin infections and Staphylococcus aureus complications in children, England, 1997-2006.Supporting decisions to increase the safe discharge of children with febrile illness from the emergency department: a systematic review and meta-analysis.Timing of positive blood samples does not differentiate pathogens causing healthcare-associated from community-acquired bloodstream infections in children in England: a linked retrospective cohort studyPrevalence of nasopharyngeal carriage of pneumococcus in preschool children attending day care in London.Health-care-associated infections in neonates, children, and adolescents: an analysis of paediatric data from the European Centre for Disease Prevention and Control point-prevalence survey.Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates.Advances in the antiviral therapy of herpes virus infection in children.Rifampicin pharmacokinetics in extreme prematurity to treat congenital tuberculosis.Chemokines and their receptors in respiratory disease: a therapeutic target for respiratory syncytial virus infection.Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland.Development and Evaluation of a Gentamicin Pharmacokinetic Model That Facilitates Opportunistic Gentamicin Therapeutic Drug Monitoring in Neonates and InfantsAcute haematogenous osteomyelitis in children: is there any evidence for how long we should treat?Postnatal cytomegalovirus: innocent bystander or hidden problem?The European Union Antibiotic Awareness Day: the paediatric perspective.Using a simple point-prevalence survey to define appropriate antibiotic prescribing in hospitalised children across the UK.PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection.
P50
Q24561535-F40755ED-59BA-40E2-B6E0-2CE97AA3AB11Q26773032-6B96454E-FC8B-447D-98F7-0A5603F3509BQ28083234-183ABA55-B9D3-4F70-A2A0-7D07AA7FE631Q28596679-D46D84F8-B3C3-46B9-AB69-7FC63A434B25Q30382350-9D1DFC85-B029-474E-A943-55CB72B551A2Q30841837-602072AB-D726-4CDA-B107-F806FF25CE0CQ31026252-0DA39663-F4D5-4E1F-9A07-153505B7F22DQ31029810-9F6292EF-B589-42F0-B7DB-C411D6F506E6Q31096335-67AA11BC-AE7F-46E3-8217-208DAE2433E1Q33510678-E080EC2B-CD0E-46F3-95B9-FEEE3F4346AFQ33575730-68182D02-911F-4C5D-8D62-4B9F43200168Q33912759-87FCE256-CB27-4741-9A5B-AAECDE6CCCA7Q34051161-FA016DE0-42B7-459A-9F34-F98709A1FEF2Q34239948-67FC4D94-8217-4B9D-B38A-54910AADA761Q34622948-9D829160-55FA-4220-A867-1E30B8047D08Q35046668-EC9B4D66-DF25-4F61-9C56-0FA447589E7DQ35065296-FF1264FA-F87E-415F-BC3E-C3F60A6C5863Q35105787-18887F59-9584-442D-82C5-A78EA36D4885Q35106819-38FA437B-F849-4E3C-95B7-67306EC45CACQ35135959-478A85A6-0A5E-478D-B611-A6F909F8CBE3Q35281135-466290E2-C90E-419F-A330-D79AE07F97C6Q35465712-67057CA1-13F8-479F-920C-FD8ECB275060Q35546534-51D2082A-14F4-481D-BAA0-A9B63EEA448AQ35593395-FC080DB1-9766-496E-A82D-70B159807D32Q35877378-B048D970-C487-4DB8-9191-E303172F6D3BQ35882201-DA6706C5-12BC-4105-B527-831248A243F2Q35936601-5FDDE4E3-AE26-409E-ABBA-D52DA1ED6C67Q36121491-DF097018-1271-459A-AE3E-F0CBF1689B08Q36250102-6AD57B13-5751-4226-8658-8E9F81B15C9DQ36684184-C140B934-95F2-48DD-BEA1-ADAD56D27EF6Q36688958-5D476B8D-BDB9-4269-B10D-42F80E7D8EDFQ36705355-6208C93C-45C3-4DA3-A6BB-FA6B790598ADQ36839725-C3E957A0-2F41-455D-AC98-1C2BBEAF624CQ37043665-E061FA0A-B693-4779-BAE9-8534847F38F1Q37120041-DD68E9B7-4F52-4DB8-B5BA-4675DEE5C296Q37151764-1D8D5181-7C80-4546-89E5-638EB4B32A4FQ37288182-884F0068-0DA1-470B-BA28-6361826DF9EAQ37305152-D7A97288-F0E9-40A6-8C5E-D9AA12FAE842Q37454764-D5ED64E9-910D-481C-9F5B-C506E3A1D830Q37624875-BE7D40D4-686F-4D5B-A515-67BB7A4DA9E2
P50
description
researcher ORCID ID = 0000-0001-8626-8291
@en
wetenschapper
@nl
name
Mike Sharland
@ast
Mike Sharland
@en
Mike Sharland
@es
Mike Sharland
@nl
type
label
Mike Sharland
@ast
Mike Sharland
@en
Mike Sharland
@es
Mike Sharland
@nl
prefLabel
Mike Sharland
@ast
Mike Sharland
@en
Mike Sharland
@es
Mike Sharland
@nl
P214
P21
P214
P31
P496
0000-0001-8626-8291
P735
P7859
lccn-no2011090476